Cargando…

Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers

Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Cusmai, Antonio, Massafra, Raffaella, Bove, Samantha, Comes, Maria Colomba, Fanizzi, Annarita, Gadaleta-Caldarola, Gennaro, Oreste, Donato, Zito, Alfredo, Giotta, Francesco, Lorusso, Vito, Palmiotti, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160897/
http://dx.doi.org/10.1177/10732748221106267
_version_ 1784719369319743488
author Rizzo, Alessandro
Cusmai, Antonio
Massafra, Raffaella
Bove, Samantha
Comes, Maria Colomba
Fanizzi, Annarita
Gadaleta-Caldarola, Gennaro
Oreste, Donato
Zito, Alfredo
Giotta, Francesco
Lorusso, Vito
Palmiotti, Gennaro
author_facet Rizzo, Alessandro
Cusmai, Antonio
Massafra, Raffaella
Bove, Samantha
Comes, Maria Colomba
Fanizzi, Annarita
Gadaleta-Caldarola, Gennaro
Oreste, Donato
Zito, Alfredo
Giotta, Francesco
Lorusso, Vito
Palmiotti, Gennaro
author_sort Rizzo, Alessandro
collection PubMed
description Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastatic BC patients has improved due to the introduction of anti-HER2 agents including trastuzumab and novel, emerging drugs and combinations such as trastuzumab deruxtecan and tucatinib – trastuzumab - capecitabine. Herein, we provide a critical overview of current clinical recommendations and emerging treatment options for metastatic HER2-positive BC, especially focusing on recently presented and published clinical trials in this setting.
format Online
Article
Text
id pubmed-9160897
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-91608972022-06-03 Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers Rizzo, Alessandro Cusmai, Antonio Massafra, Raffaella Bove, Samantha Comes, Maria Colomba Fanizzi, Annarita Gadaleta-Caldarola, Gennaro Oreste, Donato Zito, Alfredo Giotta, Francesco Lorusso, Vito Palmiotti, Gennaro Cancer Control Review Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastatic BC patients has improved due to the introduction of anti-HER2 agents including trastuzumab and novel, emerging drugs and combinations such as trastuzumab deruxtecan and tucatinib – trastuzumab - capecitabine. Herein, we provide a critical overview of current clinical recommendations and emerging treatment options for metastatic HER2-positive BC, especially focusing on recently presented and published clinical trials in this setting. SAGE Publications 2022-05-30 /pmc/articles/PMC9160897/ http://dx.doi.org/10.1177/10732748221106267 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Rizzo, Alessandro
Cusmai, Antonio
Massafra, Raffaella
Bove, Samantha
Comes, Maria Colomba
Fanizzi, Annarita
Gadaleta-Caldarola, Gennaro
Oreste, Donato
Zito, Alfredo
Giotta, Francesco
Lorusso, Vito
Palmiotti, Gennaro
Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
title Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
title_full Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
title_fullStr Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
title_full_unstemmed Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
title_short Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
title_sort systemic treatments for metastatic human epidermal growth factor receptor 2-positive breast cancer: old certainties and new frontiers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160897/
http://dx.doi.org/10.1177/10732748221106267
work_keys_str_mv AT rizzoalessandro systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT cusmaiantonio systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT massafraraffaella systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT bovesamantha systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT comesmariacolomba systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT fanizziannarita systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT gadaletacaldarolagennaro systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT orestedonato systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT zitoalfredo systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT giottafrancesco systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT lorussovito systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers
AT palmiottigennaro systemictreatmentsformetastatichumanepidermalgrowthfactorreceptor2positivebreastcanceroldcertaintiesandnewfrontiers